Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Allist Pharmaceuticals, Inc.
Revolution Medicines, Inc.
Cybrexa Therapeutics
INSYS Therapeutics Inc
Delcath Systems Inc.